Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 14/20 | 0.43 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | STAT5B | P51692 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015513 | 0.89 | NTRK1 (0.49) | JAK2NTRK1JAK3CDK2STAT5B | |
| SCHEMBL3775597 | 0.82 | JAK2 (0.48) | JAK2NTRK1JAK3CDK2STAT5B | |
| SCHEMBL3781156 | 0.82 | JAK2 (0.50) | JAK2NTRK1JAK3AURKB | |
| SCHEMBL3137650 | 0.78 | HTT (0.48) | NTRK1 | |
| SCHEMBL217487 | 0.77 | JAK2 (0.55) | JAK2NTRK1JAK3AURKB | |
| SCHEMBL3012762 | 0.75 | NTRK1 (0.50) | JAK2NTRK1JAK3CDK2STAT5B | |
| SCHEMBL220866 | 0.74 | JAK2 (0.61) | JAK2NTRK1JAK3AURKB | |
| SCHEMBL3013784 | 0.73 | NTRK1 (0.39) | JAK2NTRK1JAK3CDK2STAT5B | |
| SCHEMBL3257549 | 0.72 | NTRK1 (0.56) | JAK2NTRK1JAK3 | |
| SCHEMBL3771623 | 0.72 | NTRK1 (0.50) | JAK2NTRK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ABL1, MCL1, ETV6 | JAK2 4/4885NTRK1 4243/4885JAK3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.